# Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

> **NCT07700979** · PHASE3 · RECRUITING · sponsor: **Akeso** · enrollment: 900 (estimated)

## Conditions studied

- Gastric / Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Cadonilimab
- **DRUG:** CAPOX regimen
- **DRUG:** Nivolumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07700979
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-24
- **Primary completion:** 2029-08-18
- **Final completion:** 2030-08-18
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2026-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07700979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07700979, "Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07700979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*